DXCM FRAUD NEWS: BFA Law warns DexCom, Inc. investors who suffered losses due to approaching October 21 deadline in securities fraud class action lawsuit

Investors have until October 21, 2024, to ask the court to appoint them to preside over the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in DexCom securities. The case is pending in the U.S. District Court for the Southern District of California and is titled Alonzo v. DexCom, Inc.No. 24-cv-01485.

What is the lawsuit about?

DexCom develops glucose monitoring systems for diabetes management. The company discussed its ability to capitalize on its growth potential to achieve projected record new patient enrollments while exceeding prior fiscal year gross margins, while scaling customer conversion to its new G7 platform.

After the market closed on July 25, 2024, DexCom announced disappointing earnings results for the second quarter of 2024 and lowered its full-year revenue forecast from $4.35 billion to $4 billion-$4.05 billion. The news caused a steep drop in DexCom’s stock price. The company’s stock closed at $107.85 per share on July 25, 2024. Before the market opened on July 26, 2024, DexCom stock was trading in a range of $66.60 per share, down $41.25 per share, or 38%.

Click here for more information: https://www.bfalaw.com/cases-investigations/dexcom-inc.

What can you do?

If you have invested in DexCom, Inc., you may have legal options and are encouraged to provide your information to the company. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any legal fees or costs. The company will seek court approval for any costs and expenses.

You can submit your details via:

https://www.bfalaw.com/cases-investigations/dexcom-inc

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading global law firm representing plaintiffs in securities class action lawsuits and shareholder lawsuits. It was named one of the Top 5 Plaintiffs’ Law Firms for 2023 by ISS SCAS and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and Thompson Reuters. Among its recent notable successes, BFA has recovered over $900 million in equity from the board of directors of Tesla, Inc. (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/dexcom-inc

Advertisement of lawyer. Past results are no guarantee of future results.

To view the source version of this press release, visit https://www.newsfilecorp.com/release/221250

Dexcom shares were down $100,000 at the time of the news release. -1.71 % to 64.90EUR on the Tradegate exchange (August 27, 2024, 8:35 PM).

Diskutieren Sie über die entaltenen Werte